Schering-Plough Corp. announced today the US Food and Drug Administration has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
US Food and drug Administration issues complete response letter regarding